title: [Contrast agents in MRI-diagnosis of multiple sclerosis].
abstract: Magnetic resonance imaging using contrast agents plays an important role in diagnosis and assessment of treatment efficacy in multiple sclerosis. The development of contrast agents on the basis of gadolinium or iron oxide nanoparticles has potential for diagnosis of pathological foci (tumors, amyloid plaques, inflammation and foci of demyelination or necrosis) in nervous system diseases. Newly developing types of diagnostic substances for visualization of pathological foci in multiple sclerosis are presented in this review.
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: T O
authors.initials: TO
authors.lastname: Abakumova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Nukolova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: V P
authors.initials: VP
authors.lastname: Chekhonin
mesh_terms: D001921:Brain / Q000473:pathology; D003287:Contrast Media; D003711:Demyelinating Diseases / Q000175:diagnosis; D005290:Ferric Compounds; D005682:Gadolinium; D006801:Humans; D007249:Inflammation / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009103:Multiple Sclerosis / Q000175:diagnosis*; D053758:Nanoparticles; D058225:Plaque, Amyloid / Q000175:diagnosis
chemical_list: D003287:Contrast Media; D005290:Ferric Compounds; C000499:ferric oxide; D005682:Gadolinium